Literature DB >> 17249693

Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.

Anita Chaudhari1, Magdy Mahfouz, Arsenio M Fialho, Tohru Yamada, Ana Teresa Granja, Yonghua Zhu, Wataru Hashimoto, Beatrix Schlarb-Ridley, Wonhwa Cho, Tapas K Das Gupta, Ananda M Chakrabarty.   

Abstract

Azurin is a member of a family of metalloproteins called cupredoxins. Although previously thought to be involved in electron transfer, azurin has recently been shown to preferentially enter cancer cells than normal cells and induce apoptosis in such cells. Azurin also demonstrates structural similarity to a ligand known as ephrinB2, which binds its cognate receptor tyrosine kinase EphB2 to initiate cell signaling. Eph/ephrin signaling is known to be involved in cancer progression. We now demonstrate that azurin binds to the EphB2-Fc receptor with high affinity. We have localized a C-terminal domain of azurin (Azu 96-113) that exhibits structural similarity to ephrinB2 at the G-H loop region known to be involved in receptor binding. A synthetic peptide (Azu 96-113) as well as a GST fusion derivative GST-Azu 88-113 interferes with the growth of various human cancer cells. In a prostate cancer cell line DU145 lacking functional EphB2, azurin or its GST-fusion derivatives had little cytotoxic effect. However, in DU145 cells expressing functional EphB2, azurin and GST-Azu 88-113 demonstrated significant cytotoxicity, whereas ephrinB2 promoted cell growth. Azurin inhibited the ephrinB2-mediated autophosphorlyation of the EphB2 tyrosine residue, thus interfering in upstream cell signaling and contributing to cancer cell growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17249693     DOI: 10.1021/bi061661x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  29 in total

Review 1.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

2.  Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.

Authors:  Nafiseh Paydarnia; Shahryar Khoshtinat Nikkhoi; Azita Fakhravar; Mohsen Mehdiabdol; Hedieh Heydarzadeh; Saeed Ranjbar
Journal:  Mol Biol Rep       Date:  2019-04-01       Impact factor: 2.316

3.  Azurin-like protein blocks invasion of Toxoplasma gondii through potential interactions with parasite surface antigen SAG1.

Authors:  Arunasalam Naguleswaran; Arsenio M Fialho; Anita Chaudhari; Chang Soo Hong; Ananda M Chakrabarty; William J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 4.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

5.  Bacterial azurin in potential cancer therapy.

Authors:  Ananda M Chakrabarty
Journal:  Cell Cycle       Date:  2016-04-22       Impact factor: 4.534

Review 6.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

Review 7.  Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.

Authors:  Meng Gao; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  Protein Sci       Date:  2017-10-27       Impact factor: 6.725

Review 8.  Targeting the Eph System with Peptides and Peptide Conjugates.

Authors:  Stefan J Riedl; Elena B Pasquale
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

9.  Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.

Authors:  Nuno Bernardes; Sofia Abreu; Filomena A Carvalho; Fábio Fernandes; Nuno C Santos; Arsénio M Fialho
Journal:  Cell Cycle       Date:  2016-04-20       Impact factor: 4.534

10.  Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein.

Authors:  Yunlei Zhang; Youming Zhang; Liqiu Xia; Xiangli Zhang; Xuezhi Ding; Fu Yan; Feng Wu
Journal:  Appl Environ Microbiol       Date:  2012-08-24       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.